Add BrightSurf on Google Email

Impact Journals LLC


Oncotarget | Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

A study published in Oncotarget found that APOE genotype is associated with the presence and severity of cancer treatment-related side effects and symptoms, as well as the response to exercise-based interventions in cancer survivors. ApoE4 carriers showed a lower fall rate after exercise intervention compared to non-carriers.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateNov 22, 2022

Oncotarget | Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas

A new study analyzed tumor biopsies from patients with newly-diagnosed germinal center B cell lymphoma and found that CREBBP mutations were associated with lower disease-free survival rates. The researchers identified CLMA as a practical tool to translate experimental findings into clinical applications.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateNov 17, 2022

Aging | IGF1 gene therapy in middle-aged female rats delays reproductive senescence through its effects on hypothalamic GnRH and kisspeptin neurons

Researchers found that IGF1 gene therapy increases kisspeptin expression and GnRH release, and alters microglial cell numbers, suggesting a potential protective effect against reproductive decline. This could lead to new strategies for optimizing lifespan and combating age-related health problems in women.

SourceImpact Journals LLC·JournalAging-US·TypeExperimental study·DateNov 16, 2022

Aging | Lamin A to Z in normal aging

A new study suggests that prelamin A, a precursor of lamin A, accumulates with age and may drive normal aging. Researchers propose this protein as a target for intervention strategies to extend healthspan and lifespan.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateNov 9, 2022

Oncotarget | Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer

A study using mRNA and miRNA expression profiles identified molecular signatures that can differentiate muscle invasive bladder cancer patients who respond to neoadjuvant chemotherapy from those who do not. The research found distinct gene pathways and subtypes associated with response, which may lead to more effective treatment delivery.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateNov 8, 2022

Oncotarget | The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells

Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateNov 7, 2022

Aging | Extracellular microRNA and cognitive function in a prospective cohort of older men: The veterans affairs normative aging study

A new study has found associations between plasma miRNAs and cognitive function among cognitively normal men, including those with higher MMSE scores and slower rates of cognitive decline. These findings suggest that extracellular microRNAs may play a role in the early stages of cognitive decline.

SourceImpact Journals LLC·JournalAging-US·TypeObservational study·DateSep 15, 2022

Oncotarget | Kinase activity in renal cell carcinoma, benign renal tissue and in response to tyrosine kinase inhibitors

Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateAug 17, 2022

Oncotarget | Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma

Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateAug 11, 2022

Oncotarget | Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateAug 2, 2022

Oncotarget | Predicting cancer immunotherapy response from gut microbiomes using machine learning models

A new study uses machine learning models to predict cancer patients' responses to immunotherapy based on their gut microbiome features. The research identifies common gut bacterial taxa associated with responders versus non-responders, providing a potential tool for distinguishing and predicting immunotherapy responders.

SourceImpact Journals LLC·JournalOncotarget·TypeComputational simulation/modeling·DateJul 19, 2022

Oncotarget | Role of germline variants in the metastasis of breast carcinomas

Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateJul 13, 2022

Oncotarget | Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Abemaciclib, a CDK4 & 6 inhibitor, showed profound inhibition of cell proliferation and triggered senescence and apoptosis in breast cancer cells. Continuous dosing provided sustained inhibition with irreversible effects through apoptosis, supporting the differentiated safety and efficacy profile.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 6, 2022

Oncotarget | A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis

A recent study identified 34 novel genes that contribute to endocrine resistance in breast cancer using dynamic gene expression analysis. The researchers found that these genes are differentially expressed in both estrogen receptor-positive and triple-negative breast cancers, suggesting shared genetic mechanisms underlying resistance d...

SourceImpact Journals LLC·JournalOncotarget·TypeComputational simulation/modeling·DateJun 8, 2022

Aging-US: Hallmarks of cancer and hallmarks of aging

The article proposes a new framework for understanding the hallmarks of cancer and aging, highlighting their shared underlying principles. Dr. Blagosklonny's hyperfunction theory arranges these hallmarks in a hierarchical structure, revealing common signaling pathways involved in both aging and cancer.

SourceImpact Journals LLC·JournalAging-US·TypeLiterature review·DateMay 18, 2022

Oncoscience: Altos Labs and the quest for immortality - Dr. Blagosklonny’s perspective

Dr. Blagosklonny discusses the potential of combining rapamycin with other modalities to live long enough to benefit from future discoveries in cellular reprogramming. He emphasizes that Altos Labs needs to develop rapamycin-based drug combinations to achieve additional decades of life extension, potentially within 3-5 years.

SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateMay 11, 2022

Impact Journals at AACR Annual Meeting 2022

Impact Journals will participate as an exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting, showcasing their prominent journals Oncotarget and Aging (Aging-US). The conference focuses on Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.

Oncotarget: The antitumoral effects of chemerin

Researchers discovered chemerin, a multifunctional protein, has antitumoral properties in mouse models of cancer. Bioactive chemerin overexpression inhibits neoangiogenesis, a process distinct from normal tissue vasculature. This effect may provide a therapeutic application for targeting solid tumors.

SourceImpact Journals LLC·JournalOncotarget·DateNov 16, 2021